Drug Profile
Anti-EGFRvIII chimeric antigen receptor T cell therapy - Marino Biotechnology
Alternative Names: Anti-EGFRvIII CAR T cell therapyLatest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Beijing Sanbo Brain Hospital; Marino Biotechnology
- Developer Marino Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for phase-I development in Glioblastoma(Recurrent) in China (Parenteral)
- 01 Jul 2016 Phase-I clinical trials in Glioblastoma (Recurrent) in China (Parenteral)